141 related articles for article (PubMed ID: 9589667)
21. TPA enhances growth hormone (GH) secretion effect of GH-releasing hormone (GHRH) by human gsp-positive pituitary somatotrophinomas.
Lei T; Bai X; Hu W; Xue D; Jiang X
J Tongji Med Univ; 1999; 19(3):237-9, 248. PubMed ID: 12840904
[TBL] [Abstract][Full Text] [Related]
22. GNAS imprinting and pituitary tumors.
Mantovani G; Lania AG; Spada A
Mol Cell Endocrinol; 2010 Sep; 326(1-2):15-8. PubMed ID: 20398730
[TBL] [Abstract][Full Text] [Related]
23. Effect of gsp oncogene on somatostatin receptor subtype 1 and 2 mRNA levels in GHRH-responsive GH3 cells.
Kim E; Sohn S; Lee M; Park C; Jung J; Park S
Pituitary; 2005; 8(2):155-62. PubMed ID: 16379030
[TBL] [Abstract][Full Text] [Related]
24. The gsp oncogene disrupts Ras/ERK-dependent prolactin gene regulation in gsp inducible somatotroph cell line.
Pertuit M; Romano D; Zeiller C; Barlier A; Enjalbert A; Gerard C
Endocrinology; 2011 Apr; 152(4):1234-43. PubMed ID: 21285319
[TBL] [Abstract][Full Text] [Related]
25. Glycoprotein hormone alpha-subunit production in somatotroph adenomas with and without Gs alpha mutations.
Harris PE; Alexander JM; Bikkal HA; Hsu DW; Hedley-Whyte ET; Klibanski A; Jameson JL
J Clin Endocrinol Metab; 1992 Sep; 75(3):918-23. PubMed ID: 1517386
[TBL] [Abstract][Full Text] [Related]
26. Conditional overexpression of the wild-type Gs alpha as the gsp oncogene initiates chronic extracellularly regulated kinase 1/2 activation and hormone hypersecretion in pituitary cell lines.
Romano D; Magalon K; Pertuit M; Rasolonjanahary R; Barlier A; Enjalbert A; Gerard C
Endocrinology; 2007 Jun; 148(6):2973-83. PubMed ID: 17363453
[TBL] [Abstract][Full Text] [Related]
27. Gps mutations in Chilean patients harboring growth hormone-secreting pituitary tumors.
Johnson MC; Codner E; Eggers M; Mosso L; Rodriguez JA; Cassorla F
J Pediatr Endocrinol Metab; 1999; 12(3):381-7. PubMed ID: 10821217
[TBL] [Abstract][Full Text] [Related]
28. Preliminary study on the relationship between cAMP level and gsp expression in cultured human pituitary somatotrophinomas.
Lei T; Liu Q; Li L; Zhang L; Shu K; Xue D
J Tongji Med Univ; 2000; 20(3):214-6. PubMed ID: 11215052
[TBL] [Abstract][Full Text] [Related]
29. Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment.
Picard C; Silvy M; Gerard C; Buffat C; Lavaque E; Figarella-Branger D; Dufour H; Gabert J; Beckers A; Brue T; Enjalbert A; Barlier A
Int J Cancer; 2007 Sep; 121(6):1245-52. PubMed ID: 17514647
[TBL] [Abstract][Full Text] [Related]
30. Growth factors and human pituitary adenomas.
Spada A; Lania A
Mol Cell Endocrinol; 2002 Nov; 197(1-2):63-8. PubMed ID: 12431797
[TBL] [Abstract][Full Text] [Related]
31. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
[TBL] [Abstract][Full Text] [Related]
32. Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors.
Fragoso MC; Latronico AC; Carvalho FM; Zerbini MC; Marcondes JA; Araujo LM; Lando VS; Frazzatto ET; Mendonca BB; Villares SM
J Clin Endocrinol Metab; 1998 Jun; 83(6):2074-8. PubMed ID: 9626141
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
34. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas.
Taboada GF; Neto LV; Luque RM; Córdoba-Chacón J; de Oliveira Machado E; de Carvalho DP; Kineman RD; Gadelha MR
Neuroendocrinology; 2011; 93(1):40-7. PubMed ID: 21079388
[TBL] [Abstract][Full Text] [Related]
35. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas.
Vallar L; Spada A; Giannattasio G
Nature; 1987 Dec 10-16; 330(6148):566-8. PubMed ID: 2825031
[TBL] [Abstract][Full Text] [Related]
36. Clinical correlates in acromegalic patients with pituitary tumors expressing GSP oncogenes.
Buchfelder M; Fahlbusch R; Merz T; Symowski H; Adams EF
Pituitary; 1999 May; 1(3-4):181-5. PubMed ID: 11081196
[TBL] [Abstract][Full Text] [Related]
37. Gs protein mutations and the pathogenesis and function of pituitary tumors.
Harris PE
Metabolism; 1996 Aug; 45(8 Suppl 1):120-2. PubMed ID: 8769404
[TBL] [Abstract][Full Text] [Related]
38. Clinical and biochemical characteristics of growth hormone-secreting pituitary tumors.
Bai X; Lei T; Liu K
J Tongji Med Univ; 2000; 20(3):212-3. PubMed ID: 11215051
[TBL] [Abstract][Full Text] [Related]
39. The cyclic adenosine 3',5'-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas.
Bertherat J; Chanson P; Montminy M
Mol Endocrinol; 1995 Jul; 9(7):777-83. PubMed ID: 7476961
[TBL] [Abstract][Full Text] [Related]
40. Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas.
Ronchi CL; Peverelli E; Herterich S; Weigand I; Mantovani G; Schwarzmayr T; Sbiera S; Allolio B; Honegger J; Appenzeller S; Lania AG; Reincke M; Calebiro D; Spada A; Buchfelder M; Flitsch J; Strom TM; Fassnacht M
Eur J Endocrinol; 2016 Mar; 174(3):363-72. PubMed ID: 26701869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
